Fig. 6.
The synergistic antitumor effect of sorafenib and CuB in the HepG2 xenograft model. Following treatment with sorafenib (25 mg·kg−1) by gavage once a day and/or CuB (0.75 mg·kg−1) by intraperitoneal injection every other day, nude mice were killed on day 21 and tumors were excised. (A, B) Tumor volumes, (C) tumor weights and (D) body weights of the tumor‐bearing mice in each group. Data are presented as the mean ± SD from three independent experiments. Differences between two groups were analyzed using Student’s t‐test. **P < 0.01, ***P < 0.001 and ****P < 0.0001 vs. the corresponding group.